<DOC>
	<DOCNO>NCT02256475</DOCNO>
	<brief_summary>This Phase 1b , open-label , multiple-dose study safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) NBI-98854 total 36 pediatric subject Tourette syndrome ( TS ) . The study conduct approximately 18 male female child ( 6 11 year age ) approximately 18 male female adolescent ( 12 18 year age ) . Both age group divide equally 3 dose cohort 6 subject . Ascending dos evaluate part staggered-cohort design . Study drug administer cohort 14 consecutive day .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics NBI-98854 Children Adolescents With Tourette Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<criteria>1 . Have documentation write informed consent , write witnessed assent subject write informed consent subject 's parent legal guardian . 2 . Be good general health . 3 . Have Diagnostic Statistical Manual Mental Disorders diagnosis Tourette Syndrome ( DSMIV V ) . 4 . Have TS symptom impair school , occupational , and/or social function . 5 . If medication use treat TS symptom , must stable dos medication minimum 30 day baseline ( Day 1 ) , medication regimen expect remain stable throughout study period . The use tetrabenazine treat TS symptom prohibit . 6 . Subjects childbearing potential practice total abstinence must instruct proper use barrier method contraception agree use hormonal two form nonhormonal contraception consistently screen 30 day last dose study drug . 7 . Adolescent subject ( 12 18 year age ) must negative urine drug screen amphetamine , barbiturate , benzodiazepine , phencyclidine , cocaine , opiates , cannabinoids . Subjects stable dos prescribe benzodiazepine , opiate , psychostimulants allow participate study . 8 . Adolescent subject ( 12 18 year age ) must negative alcohol breath test . 9 . Be willing able adhere study regimen study procedure describe protocol inform consent/assent form , include requirement study center return followup visit . 1 . Have unstable medical condition chronic disease . 2 . Had medically significant illness within 30 day screen . 3 . Excessive use tobacco and/or nicotinecontaining product . 4 . Have history substance ( drug ) dependence substance alcohol abuse . 5 . Are currently pregnant lactating . 6 . Have know history neuroleptic malignant syndrome . 7 . Have know history long QT syndrome cardiac tachyarrhythmia . 8 . Have cancer diagnosis within 3 year prior screen , exception localize skin cancer carcinoma situ cervix . 9 . Have receive investigational drug within 30 day screen plan use investigational drug ( NBI98854 ) study . 10 . Have significant risk suicidal violent behavior .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>